NCT03643107 2025-01-23
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Allarity Therapeutics
Phase 2 Completed
Clinical Trials
1 trialsInterventional × Metastatic Castration-Resistant Prostate Cancer Patients × Prednisolone × Clear all